Search
flotetuzumab
Indications:
- acute myeloid leukemia (AML)
Dosage:
- 500 ng/kg/day by continuous infusion over 7 days for each cycle (max)
Adverse effects:
- infusion-related reactions
- cytokine release syndrome
- tocilizumab (Acterma) successful at decreasing severity & incidence of cytokine release syndrome
- pancytopenia
Mechanism of action:
- dual-affinity re-targeting, or DART, molecule aimed at CD123, the alpha subunit of the IL-3 receptor expressed on a majority of myeloid blast cells & leukemic stem cells*
* CD123 is also expressed on monocytes, B cells, megakaryocytes, & plasmacytoid dendritic cells, & in smaller amounts on normal hematopoietic stem cells & hematopoietic progenitors
* CD123 has been detected >90% of blasts in patients with AML
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- O'Neil A
CD123-Targeted Flotetuzumab Induces Some CRs in AML.
DART molecule aimed at receptor expressed on most myeloid blast
and leukemic stem cells.
MedPage Today Oct 11, 2017
https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/68470